Aesthetic outcome of intralesional injection of lauromacrogol as a single‐agent treatment for uncomplicated infantile hemangiomas: A long‐term follow‐up study

• Published in: Journal of dermatology Vol. 47; no. 10; pp. 1119 - 1125
• Main Authors: Lin, Peng‐Fei, Chen, Fa‐Chun, Chen, Jia‐Yao, Jiang, Cheng‐Hong
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.10.2020
• Subjects: Aesthetics; Birthmarks; Child; Complications; Esthetics; Follow-Up Studies; Hemangioma; Hemangioma - drug therapy; Humans; Hyperpigmentation; Infant; infantile hemangioma; Injection; Injections, Intralesional; intralesional; lauromacrogol; Pigmentation; Polidocanol; Retrospective Studies; sequelae; Skin Neoplasms - drug therapy; Surgery; Topical medication; Treatment Outcome; sequelae; infantile hemangioma; intralesional; aesthetics; lauromacrogol
• ISSN: 0385-2407; 1346-8138
• DOI: 10.1111/1346-8138.15473

Infantile hemangiomas (IH) are at risk of incomplete regression with remnant permanent sequelae, ranging from passive waiting for spontaneous regression to active systemic administration. The application of traditional therapy involving injection of a sclerosing agent is limited due to the difficulty in achieving cosmetic improvement. This study aimed to explore a new injection method that could not only promote tumor regression but also achieve cosmetic improvement. A total of 122 IH (from 109 children) injected intralesionally with lauromacrogol in the Plastic Surgery Department of Fujian Medical University Union Hospital between 1 January 2012 and 1 June 2019 were enrolled in this study. The mean follow‐up time was 2.9 years. Of 122 lesions studied, 111 (91.0%) achieved complete regression, 10 (8.2%) achieved significant regression and one (0.8%) achieved moderate regression. In terms of aesthetic appearance, 70 (57.4%) IH had no sequelae and the A score was 5/5. Twenty‐one (17.2%) IH had minimal hyperpigmentation, hypopigmentation or telangiectasia and the A score was 4/5. Thirty‐one (25.4%) IH had left mild or relatively obvious sequelae and the A score was 1–3/5. None of the 122 IH involved had rebound growth after terminating the treatment. Hyper‐ or hypopigmentation gradually faded over time and part of the IH had already returned to normal appearance by the time of long‐term follow up. The results indicated that this new type of injection therapy significantly promoted the regression of uncomplicated IH and helped achieve the expected cosmetic appearance.